| Immunization of Mice with Urease Vaccine Affords Protection against Helicobacter pylori Infection in the Absence of Antibodies and Is Mediated by MHC Class II … TH Ermak, PJ Giannasca, R Nichols, GA Myers, J Nedrud, R Weltzin, ... The Journal of experimental medicine 188 (12), 2277-2288, 1998 | 484 | 1998 |
| A recombinant vesicular stomatitis virus Ebola vaccine JA Regules, JH Beigel, KM Paolino, J Voell, AR Castellano, Z Hu, ... New England Journal of Medicine 376 (4), 330-341, 2017 | 446 | 2017 |
| Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori–infected adults P Michetti, C Kreiss, KL Kotloff, N Porta, JL Blanco, D Bachmann, ... Gastroenterology 116 (4), 804-812, 1999 | 405 | 1999 |
| The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial A Huttner, JA Dayer, S Yerly, C Combescure, F Auderset, J Desmeules, ... The Lancet Infectious Diseases 15 (10), 1156-1166, 2015 | 315 | 2015 |
| Clinical proof of principle for ChimeriVax™: recombinant live, attenuated vaccines against flavivirus infections TP Monath, K McCarthy, P Bedford, CT Johnson, R Nichols, S Yoksan, ... Vaccine 20 (7-8), 1004-1018, 2002 | 278 | 2002 |
| A live, attenuated recombinant West Nile virus vaccine TP Monath, J Liu, N Kanesa-Thasan, GA Myers, R Nichols, A Deary, ... Proceedings of the National Academy of Sciences 103 (17), 6694-6699, 2006 | 259 | 2006 |
| Live attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in … F Guirakhoo, S Kitchener, D Morrison, R Forrat, K McCarthy, R Nichols, ... Human vaccines 2 (2), 60-67, 2006 | 252 | 2006 |
| Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and … TP Monath, F Guirakhoo, R Nichols, S Yoksan, R Schrader, C Murphy, ... The Journal of infectious diseases 188 (8), 1213-1230, 2003 | 235 | 2003 |
| Safety and Immunogenicity of Increasing Doses of aClostridium difficile Toxoid Vaccine Administered to Healthy Adults KL Kotloff, SS Wasserman, GA Losonsky, W Thomas Jr, R Nichols, ... Infection and immunity 69 (2), 988-995, 2001 | 233 | 2001 |
| Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. TP Monath, R Nichols, WT Archambault, L Moore, R Marchesani, J Tian, ... The American journal of tropical medicine and hygiene 66 (5), 533-541, 2002 | 216 | 2002 |
| Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection H Kleanthous, GA Myers, KM Georgakopoulos, TJ Tibbitts, JW Ingrassia, ... Infection and Immunity 66 (6), 2879-2886, 1998 | 179 | 1998 |
| Clonal vaccinia virus grown in cell culture as a new smallpox vaccine R Weltzin, J Liu, KV Pugachev, GA Myers, B Coughlin, PS Blum, ... Nature medicine 9 (9), 1125-1130, 2003 | 165 | 2003 |
| Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys TP Monath, I Levenbook, K Soike, ZX Zhang, M Ratterree, K Draper, ... Journal of virology 74 (4), 1742-1751, 2000 | 165 | 2000 |
| ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)–a second-generation smallpox vaccine for biological defense TP Monath, JR Caldwell, W Mundt, J Fusco, CS Johnson, M Buller, J Liu, ... International journal of infectious diseases 8, 31-44, 2004 | 158 | 2004 |
| Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV A Rechtien, L Richert, H Lorenzo, G Martrus, B Hejblum, C Dahlke, ... Cell reports 20 (9), 2251-2261, 2017 | 121 | 2017 |
| Safety and immunogenicity of the rVSV∆ G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose … DG Heppner, TL Kemp, BK Martin, WJ Ramsey, R Nichols, EJ Dasen, ... The Lancet Infectious diseases 17 (8), 854-866, 2017 | 121 | 2017 |
| Yellow fever 17D vaccine safety and immunogenicity in the elderly TP Monath, MS Cetron, K McCarthy, R Nichols, WT Archambault, L Weld, ... Human vaccines 1 (5), 207-214, 2005 | 121 | 2005 |
| Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (ARILVAXTM and YF-VAX (R … VE Belmusto-Worn, JL Sanchez, K McCARTHY, R Nichols, CT Bautista, ... American Journal of Tropical Medicine and Hygiene 72 (2), 189-197, 2005 | 104 | 2005 |
| Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers S Banerjee, A Medina-Fatimi, R Nichols, D Tendler, M Michetti, J Simon, ... Gut 51 (5), 634-640, 2002 | 103 | 2002 |
| A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults AW Artenstein, C Johnson, TC Marbury, D Morrison, PS Blum, T Kemp, ... Vaccine 23 (25), 3301-3309, 2005 | 100 | 2005 |
Donald Gray HeppnerVaxxinity, Inc.Verified email at vaxxinity.com
